. The pre-S 2 mutant large HBV surface antigen (LHBS) in type II ground glass hepatocytes (GGHs) has been recognized as an emerging viral oncoprotein; it directly interacts with the c-Jun activation domain-binding protein 1 (JAB1) and subsequently causes hyperphosphorylation of the tumor-suppressor retinoblastoma and, consequently, leads to disturbed cell cycle progression. The interaction of the pre-S 2 mutant LHBS with JAB1 could provide a potential target for chemoprevention. In this study, we found that the preneoplastic type II GGHs showed a significant decrease of the cyclindependent kinase inhibitor p27 Kip1 , which serves as a marker for pre-S 2 mutant-JAB1 complex formation. The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) elevated expression of the tumor-suppressor thioredoxin-binding protein 2 (TBP2), which subsequently enhanced the JAB1-TBP2 interaction and abolished the pre-S 2 mutant LHBS-induced degradation of p27 Kip1 , which, in turn, recovered the normal cell cycle checkpoint. The pre-S 2 mutant LHBS-induced pro-oncogenic effects: increased cell proliferation, nuclear/cytoplasmic ratio and proliferating cell nuclear antigen expression, were all greatly ameliorated after SAHA treatments, which suggested SAHA as a promising chemopreventive agent for the pre-S 2 mutant oncoprotein-induced HCC. In conclusion, this study provides the mechanism of histone deacetylase (HDAC) inhibitor in preventing the pre-S 2 mutant-induced oncogenic phenotype. The HDAC inhibitor SAHA is therefore a potential chemopreventive agent for high-risk chronic HBV patients who may develop HCC.
Introduction
Chronic viral hepatitis is the major cause of hepatocellular carcinoma (HCC), the most frequent visceral neoplasm worldwide. The main causative agents for HCC are chronic hepatitis B virus (HBV) and HCV, which together are responsible for the majority of HCC in humans. These viruses cause necroinflammatory liver disease of variable duration and severity. A major portion of the viral hepatitis progresses into liver cirrhosis and dysplasia, and ultimately into HCC. In this process, the viral proteins are believed to be important players that cross talk with various host proteins, which affects the host signaling pathways. A number of HBV gene products have been identified as viral tumor proteins. The X protein (pX) is oncogenic because it activates a variety of carcinogenesis relevant cellular and viral promoters through direct binding to transcription factors and coactivators. HBX also stimulates the Src, Ras, NF-κB, and NF-AT signaling pathways (1) (2) (3) (4) (5) . In addition, the HBV large surface antigen (LHBS) causes strong and sustained hepatocyte proliferation in the chronic phase of HBV infection in transgenic mice and is, therefore, highly associated with HCC incidence (6) .
The large form of HBV surface (HBS) antigen, which includes an additional pre-S region that is the upstream promoter region for the small form, is predominantly expressed in the late phase of chronic HBV infection (7) . In this stage, there emerges the pre-S 2 mutant LHBS that is truncated of ~17 amino acids in the N-terminus of the pre-S 2 region, and often also contains a point mutation in the start codon of the region, which leads to a dramatic decrease in the synthesis of the middle form of HBS (8, 9) . The pre-S 2 mutant LHBS contributes to the histological morphology of the type II GGH, which exhibited growth advantage and have been recognized as preneoplastic lesions (10, 11) . Therefore, the pre-S 2 mutant LHBS has been associated with hepatocarcinogenesis and represents a HBV viral oncoprotein (12) .
Earlier studies (12, 13) found that HBV carriers who presented with the pre-S 2 mutant LHBS in serum were predisposed to advanced liver diseases including liver cirrhosis and HCC. We found that the pre-S 2 mutant LHBS accumulates in endoplasmic reticulum (ER) and induces strong endoplasmic reticulum stress, which induces oxidative stress, DNA damage and mutagenesis, all of which cause genomic instability in hepatocytes (10, 14) . The pre-S 2 mutant LHBS also induces overexpression of cyclin A, which causes cell cycle progression in the presence of DNA lesions (15) . We also recently found that the pre-S 2 mutant LHBS directly interacts with c-Jun activation domain-binding protein 1 (JAB1) and subsequently causes hyperphosphorylation of the tumor-suppressor retinoblastoma and, consequently, G 1 to S phase cell cycle progression (16) . JAB1 is a key subunit of the COP9 signalosome and acts as a multifunctional protein associated with the signaling pathway, cell cycle regulation and development (16) . JAB1 promotes cell proliferation by activating AP-1 transcription and stimulates cell cycle progression by increasing the degradation of the cyclin-dependent kinase inhibitor p27
Kip1 (17) . The interaction of the pre-S 2 mutant LHBS with JAB1 is, therefore, an important mechanism for the carcinogenic process associated with it. Intrusion to disrupt the pre-S 2 mutant-JAB1 complex using a chemical method could potentially provide a chemopreventive approach to inhibit the prooncogenic property contributed by the pre-S 2 mutant LHBS.
HBV infection-associated HCC is usually multifocal and therefore difficult to surgically eradicate. Patients who received surgical resection had high recurrence rates. Our earlier study found that the type II ground glass hepatocytes (GGHs) harboring pre-S 2 mutant LHBS represent preneoplastic lesions preceding HCC (10, 11) . Recently, we also found that the presence of type II GGHs predicts the recurrence of HCC after surgery (18) . The type II GGHs are therefore high-risk markers for HCC in chronic HBV carriers and recurrence after hepatectomy surgery. Because HBV-induced HCC usually develops many years after the initial infection, it allows time for a chronic HBV carrier to uptake a chemopreventive approach, which prevents HBV (+) hepatocyte transformation and carcinogenesis (19) .
Pre-S 2 mutant LHBS is highly prevalent in the late phase of chronic HBV infection and HCC, and the hepatocytes harboring it stand out as those most susceptible to cancer (20) . Therefore, developing a chemopreventive approach that targets these cells is important. JAB1 interacts with the tumor-suppressor thioredoxin-binding protein 2 (TBP2), which forms a competitive binding with the JAB1-p27
Kip1 complex and stabilizes p27 Kip1 (21) . We, therefore, hypothesized that TBP2 could serve as a molecular target for p27 stabilization. A previous study reported that the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) increased TBP2 in human prostate and bladder cancer cells (22) . HDAC inhibitors have also been well known to present with a wide substrate spectrum, including various HDACs, p53, c-Myc, etc. (23) . The concerted actions of HDAC inhibitors on these molecules inhibit tumor cell proliferation and division; whereas they mostly cause little harm to non-cancerous cells (23) . SAHA, a potent HDAC inhibitor, has been approved for treating some cancers, such as cutaneous T-cell lymphoma (24) . In this study, we studied the molecular mechanism of how SAHA regulates TBP2 levels in liver cells. We also examined whether by increasing the TBP2 level, SAHA could recover the normal p27
Kip1 level that was aberrantly lowered by pre-S 2 mutant LHBS. This allowed us to investigate the potential of SAHA as a chemopreventive agent for high-risk chronic HBV patients who may develop HCC or whose HCC may recur after surgery.
Materials and methods

HCC patients and cell lines
Non-tumorous liver sections were collected with informed consent from the HCC patients admitted to National Cheng Kung University Hospital, for hepatectomy surgery from 2005 to 2009. Human hepatoma HuH7, immortalized non-cancerous hepatocyte WRL-68, and bladder cancer T24 cell lines were used for in vitro cell culture studies. These cells were transiently transfected with the wild-type and pre-S 2 mutant LHBS, cloned in the pIRES-hrGFP-2a plasmid vector (Stratagene), which contained the hemagglutinin epitope (HA). Also, to establish stable cell lines expressing wild-type and pre-S 2 mutant LHBS, the LHBS gene was cloned into pQCXIP retroviral vector (Clontech) then transferred into cells, following a protocol described previously [11] . TBP2 small interfering (siRNA) in the lentiviral vector pLKO.1, provided by the RNAi Core Facility at the Academia Sinica (Taipei, Taiwan), was transferred into the human cells, based on a protocol described previously (25) .
The pre-S gene chip
The protocols for detecting pre-S gene deletions using the pre-S gene chip, developed in our laboratory, are described previously (20) . Briefly, the pre-S LHBS gene was PCR amplified by using the 5′-digoxigenin-labeled primers then incubated with a pre-S gene chip in a 24-well culture plate in microarray hybridization buffer [5× saline sodium citrate, 1% blocking reagent (Roche), 0.1% N-lauroylsarcosine, 0.02% sodium dodecyl sulfate (SDS)]. The digoxigenin that had hybridized to the DNA probes on the chip was then recognized by incubating the chip with the anti-digoxigenin-alkaline phosphatase Fab fragments (Roche), followed with the alkaline phosphatase substrates nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate. After the reactions, chip images were scanned using an Epson Perfection 1250 scanner.
Immunohistochemical staining
Immunohistochemical staining of HBS using the rabbit anti-HBS antibodies (Abcam) was done in the 5 µm sections of paraffin-embedded liver tissue from humans, pre-S 2 mutant LHBS transgenic mice and C57BL/6 mice, based on a protocol described previously (17) . To detect proliferating cell nuclear antigen (PCNA), an antibody against PCNA (Santa Cruz) was used, followed with the same signal visualization method used for HBS.
Immunofluorescent staining
Five micrometer frozen liver sections from the non-tumorous regions of HBV (+) HCC patients were fixed in acetone for 15 min, and then immunostained with anti-p27 (R&D Systems) and anti-HBS (Abcam) antibodies, following protocols described previously (17) .
Yeast two-hybrid assays
The JAB1 and various truncated pre-S 2 mutant LHBS genes were amplified using a PCR and then cloned into the pACT2 and pGBKT7 yeast twohybrid vectors (BD Clontech), respectively, using NdeI and SalI restriction enzymes. The protocols for yeast two-hybrid assays are described elsewhere (17) . Briefly, JAB1/pACT2, which contained the Gal4 activation domain, and the various pre-S 2 mutant LHBS/pGBKT7, which contains the Gal4 DNAbinding domain, were cotransformed into AH109 yeast strain, and then tested for their ability to grow in the histidine-selective medium. The yeast containing the truncated pre-S 2 mutant LHBS constructs that interacted with JAB1 could grow in the histidine-selective medium.
Western blotting
HuH7 cells expressing wild-type or pre-S 2 mutant LHBS were treated with 5 µM of SAHA (Cayman Chemicals) for 24 h. The LHBS was detected using the mouse monoclonal antibody recognizing HA, tagged to the LHBS gene. The protocols for western blotting are described elsewhere (15) .
Reverse transcription-PCR
Liver sections from the transgenic mice carrying the pre-S 2 mutant LHBS and the control C57BL/6 mice were used for RNA extraction following a protocol described previously (17) . The reverse transcription-PCR (RT-PCR) protocol is described elsewhere (15) . PCR primers used for the human and mouse genes were p27, forward: 5′-atgtcaaacgtgcgagtgtc-3′, and reverse: 5′-tcgaaattccacttgcgctg-3′; HBS, pre-S 1 region, forward: 5′-acgcagatctcaatcgccgc-3′, and reverse: 5′-cgcaaaatgatgcgctacgt-3′; TBP2, forward: 5′-atggtgatgttcaagaagat-3′, and reverse: 5′-tatttgtttccaggtctcat-3′; PCNA, 5′-aacctgcagagcatggactc-3′, and reverse: 5′-acagctgtactcctgttctg-3′; β-actin, forward: 5′-atcatgtttgagaccttcaa-3′, and reverse: 5′-catctcttgctcgaagtcca-3′.
Co-immunoprecipitation assays
Protocols for co-immunoprecipitation experiments for LHBS were described previously (15) . Briefly, to pull-down LHBS, mouse anti-HA epitope antibody and protein A/G agarose beads (Santa Cruz Biotechnology) were mixed with cell-free extracts of HuH-7 cells transfected with the wild-type or pre-S 2 mutant LHBS mutant genes. Immunoprecipitants were repeatedly washed with radioimmunoprecipitation assay buffer [150 mmol/l NaCl, 10 mmol/l Tris (pH 7.2), 0.1% SDS, 1.0% Triton X-100, 1% deoxycholate and 5 mmol/l EDTA] supplemented with protease inhibitor cocktail (Sigma-Aldrich), and then analyzed by western blotting.
Luciferase reporter assays for TBP2 promoter activities
HuH7 cells were cotransfected with the wild-type, pre-S 2 mutant LHBS or the plasmid vector, and the pGL-3 luciferase reporter plasmids carrying various TBP2 promoter regions (22) . After transfections for 24 h, the culture media were replaced with fresh media containing 5 µM of SAHA or vehicle [dimethyl sulfoxide (DMSO)]. After incubation for another 24 h, the cells were harvested and the luciferase activities were measured using Luciferase Assay System (Promega).
DNA affinity purification assay (DAPA)
Oligonucleotides containing the two putative nuclear transcription factor Y (NF-Y)-binding sites at the -450 and -415 promoter regions of TBP2 gene were synthesized and biotinylated. Their complementary oligonucleotides were also synthesized then annealed to them as probes for DNA affinity purification assay (DAPA) analysis. The wild-type and mutant probes used were wild-type (-450 region): 5′-aggagcccgaccaatcagtgagat, mutant (-450 region): 5′-aggagcccgactactcagtgagat, wild-type (-415 region): 5′-acatccctcccattggctgcccggt, and mutant (-415 region): 5′-acatccctcccagtagctgcccggt. The underlined regions indicate the NF-Y-binding sites. To perform DAPA, cell nuclear proteins were incubated with biotinylated double-stranded probes at 37ºC for 2 h. The DNA-protein complexes were then pulled down using streptavidin beads (GenScript) then analyzed by western blotting using NF-YA antibody (GenScript).
Cell cycle analysis
Protocols for cell cycle analysis are described elsewhere (17) . HuH7, T24 and WRL-68 cells stably expressing wild-type or pre-S 2 mutant LHBS were treated with 5 µM of SAHA for 24 h then analyzed for cell cycle profiles. To detect cell cycle profiles, cells were harvested by trypsinization, washed twice with phosphate-buffered saline (pH 7.4), fixed with ice-cold 70% ethanol overnight, and then stained with propidium iodine (40 μg/ml) supplemented with RNase A (0.1 mg/ml) for 10 min at room temperature. The cell cycle profiles were detected by FACScan flow cytometry (Becton Dickinson). The percentages of cells in the G 1 , S and G 2 to M phases were measured by using the WinMDI software.
Colony formation assays
One thousand HuH7 or WRL-68 cells stably expressing wild-type or pre-S 2 mutant LHBS were seeded in a 10 cm cell culture plate with growth medium containing SAHA (1 µM) or the vehicle control DMSO. The cells were maintained for 2 weeks, and growth medium was changed every 3 days. The surviving cell colonies were then stained with crystal violet (1%) and counted.
Histone deacetylase inhibitor SAHA suppresses the pro-oncogenic effects
Pre-S 2 mutant LHBS transgenic mice
The transgenic and the control C57BL/6 mice were maintained in the animal facility in National Cheng Kung University medical center and fed standard laboratory chow and water ad libitum based on Taiwan National Science Council guidelines. Sera from these mice were routinely examined for ALT levels (GPT/ ALT-PIII kit; Fujifilm). Liver sections taken from six transgenic and six control C57BL/6 mice at 6-months old were examined for LHBS expression levels using western blotting with a mouse antibody targeting the pre-S 1 region (generously provided by Trai-Ming Yeh, PhD, National Cheng Kung University). Western blotting was also used to detect other proteins in mouse livers (15) .
SAHA treatment of the pre-S 2 mutant LHBS transgenic mice
Five 6-month-old pre-S 2 mutant LHBS transgenic mice and five age-and sex-matched C57BL/6 control mice were intraperitoneally (i.p.) injected with SAHA (50 mg/ml/day) or vehicle (33.3% DMSO) and 66.7% of 0.01 M phosphate buffer (pH 7.4) for 14 days before they were euthanized.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assays
Five micrometer paraffin-embedded liver sections were detected for apoptosis using the TUNEL Detection Kit (TACS TdT; R&D Systems).
Results
Pre-S 2 mutant LHBS-mediated p27
Kip1 degradation in type II GGHs of HCC patients To specifically detect the pre-S gene deletions in GGH nodules, we did immunohistochemical staining for HBS antigen in the non-tumorous sections of the HCC tissue samples. Type I GGHs, sporadically scattered, and type II GGHs, clustered as nodules, were observed ( Figure 1A , Supplementary Figure 1 , available at Carcinogenesis Online). An analysis, using Pre-S Gene Chips, of isolated morphologically normal hepatocytes and GGHs showed that type I and type II GGHs harbored deletions in the pre-S 1 and -S 2 regions, respectively, and that normal hepatocytes did not express pre-S mutant LHBS, which showed a high correlation between GGH morphology and pre-S deletions ( Figure 1B ). p27
Kip1 had been found degraded by pre-S 2 mutant LHBS in cell cultures in vitro (17) . Immunofluorescent analysis of p27 Kip1 in the sections containing type I and type II GGHs showed that type II GGHs (clustered) had lower p27
Kip1 levels than type 1 GGHs (sporadic) or the hepatocytes that did not harbor HBS antigen did ( Figure 1C, Supplementary Figure 2 , available at Carcinogenesis Online). In total, 84.6% (11 of 13) of the type II GGH sections and none (0 of 9) of the type I GGH sections examined showed a decrease in p27 Kip1 . This finding indicates that a p27
Kip1 decrease is specifically prevalent in the type II GGH cells in HCC patients and can potentially serve as a biomarker for pre-S 2 mutant LHBS-induced HCC.
Requirement of amino acids 61-119 in pre-S 2 mutant oncoprotein for JAB1-induced p27
Kip1 degradation in GGHs To characterize the protein interactions between JAB1 and pre-S 2 mutant oncoprotein, we mapped the pre-S 2 mutant LHBS domain that directly binds to JAB1 using yeast two-hybrid assays. Consistent with our earlier findings (17), the pre-S 2 mutant LHBS binds to JAB1, as the yeast cells carrying these two proteins expressed the Gal4 promoter-driven histidine reporter gene and grew in the histidine-selective medium (Figure 2A) . Analyses of the serially truncated pre-S 2 mutant LHBS constructs found that the truncated proteins maintained their affinities to JAB1, except the one truncated in the region spanning amino acid (a.a.) 61-119, which indicated that a.a. 61-119 was the interactive domain for binding to JAB1. The proteins truncated in the regions spanning a.a. 61-90 and a.a. 91-119 lost most of their abilities to bind with JAB1, which showed that the interactive domain spans a.a. 61-119 ( Figure 2B ). Amino acid 61-119 is in the pre-S 1 promoter region; therefore, the pre-S 2 mutant LHBS is associated with JAB1 through the pre-S 1 region, and this is specific to the large form of HBS ( Figure 2C ). Requirement of this domain for the interaction between the two proteins in vivo was also confirmed using co-immunoprecipitation assays, which showed that, unlike the full-length protein, the pre-S 2 mutant LHBS truncated in this domain was not associated with JAB1 ( Figure 2D ). We previously reported that pre-S 2 mutant LHBS induced JAB1-dependent p27
Kip1 degradation and disturbed cell cycle checkpoints in transgenic mice (17) . In this study, we found that this effect was dependent on the interaction between JAB1 and pre-S 2 mutant LHBS, because the p27 Kip1 level in the truncated protein (Δ2
Δ61-119
, Figure 2E ), which no longer bound to JAB1, recovered to that in the control cells (V; Figure 2E ), which contained vehicle plasmid only. MG132, a 26S proteasome inhibitor, was added to the pre-S 2 mutant LHBS (+) cells to show that the observed p27 Kip1 decrease was indeed caused by the proteasome-mediated degradation (Δ2 versus Δ2 w/MG132, Figure 2E ). We previously reported that pre-S 2 mutant LHBS caused phosphorylation on threonine 160 residue of the G 1 to S phase cell cycle regulator Cdk2 as a result of p27
Kip1 degradation (17) . In this study, we found that in the cells carrying truncated pre-S 2 mutant LHBS (Δ2
; Figure 2E ), the Cdk2 phosphorylation on the threonine 160 residue was greatly inhibited (∆2 versus Δ2 Δ61-119 in the panel of CDK2 T160
; Figure 2E ). These results clearly demonstrated that the a.a. 61-119 region of the pre-S 2 mutant LHBS was essential for JAB1-mediated p27
Kip1 degradation in type II GGHs.
SAHA induced TBP2-mediated p27
Kip1 recovery in pre-S 2 mutant hepatocytes It was previously reported that the HDAC inhibitor SAHA induced expression of TBP2, which binds to p27 Kip1 (22) . We, therefore, hypothesized that, by increasing the TBP2 level with an HDAC inhibitor, the level of p27
Kip1 would recover to a normal state in pre-S 2 mutant LHBS (+) hepatocytes. Indeed, in the pre-S 2 mutant LHBS (+) HuH7 cells treated with SAHA, we found that the TBP2 RNA and protein levels were both greatly increased, concordantly with p27
Kip1 protein increase ( Figure 3A and B), indicating that TBP2 was transcriptionally upregulated by SAHA. Some pre-S 2 mutant LHBS-induced pro-oncogenic effects: cyclin A overexpression, Cdk2 T160 phosphorylation and retinoblastoma hyperphosphorylation, reported by us, were greatly inhibited after SAHA treatments ( Figure 3A and B) . It was reported (22) that SAHA activated TBP2 transcription through the nucleotide -482 to -264 promoter regions of the gene, which contains two putative binding sites to NF-Y and one to SP1 transcription factors. We found that, mutation in either of the two NF-Y binding sites dramatically inhibited the SAHA-induced TBP2 transcriptional activation, and mutations in both sites nearly completely abolished this effect ( Figure 3C ). However, mutation in the SP1 binding site only mildly inhibited this effect ( Figure 3C ). These findings suggested that NF-Y is the main transcription factor regulating SAHA-induced TBP2 expression. By DAPA analysis, it was found that SAHA treatments greatly increased the binding of NF-Y to both oligonucleotide probes containing the either NF-Y binding sites but not the ones where the NF-Y binding sites were mutated ( Figure 3D ). These findings revealed that SAHA-induced TBP2 expression through enhancing NF-Y transcription factor binding to the gene promoter.
We also found that, in the pre-S 2 mutant LHBS (+) cells treated with SAHA, the knockdown of TBP2 expression with a specific siRNA brought the levels of p27
Kip1 protein and Cdk2 T160 phosphorylation back to those before SAHA treatment ( Figure 3E ), indicating that inhibiting HDAC activities efficiently recovered the normal functions of the cell cycle regulators p27
Kip1 and Cdk2 through a TBP2-dependent pathway. Co-immunoprecipitation assays showed that SAHA increased the association of JAB1 with TBP2 ( Figure 3F) . Also, to precisely detect the binding of JAB1 with p27
Kip1
, cells were treated with the 26S proteasome inhibitor MG132 to block p27
Kip1 degradation, and then treated with SAHA or otherwise the solvent DMSO. It was found that SAHA decreased the JAB1-p27
Kip1 interaction, which was aberrantly high in pre-S 2 mutant LHBS (+) cells (Δ2 w/SAHA versus Δ2 w/ DMSO; Figure 3G ). Taking these findings together, through its activity as an HDAC inhibitor, SAHA restored the normal G 1 to S cell cycle checkpoint that was disrupted by pre-S 2 mutant LHBS.
SAHA restored normal cell cycle checkpoints and proliferation hindered by pre-S 2 mutant LHBS
Cell cycle profile analysis found that pre-S 2 mutant LHBS (+) cancerous T24 cells and non-cancerous WRL-68 hepatocytes showed ), or vector plasmid-only (V) were subjected to immunoprecipitation using anti-HA antibody, followed by western blotting. (E) The levels of p27 Kip1 , CDK2 and CDK2 T160 phosphorylation in HuH7 cells transfected with full-length and truncated pre-S 2 mutant LHBS, detected using western blotting. Lane 5, cells pretreated with the proteasome inhibitor MG132 (10 µM) for 4 h before harvest. α-Tubulin was the internal control. T24 and WRL-68 cells, respectively (control w/DMSO versus ∆2 w/ DMSO in G 1 and S phases; Figure 4A and B), which was consistent with our previous findings (17) . However, SAHA treatment significantly decreased the G 1 to S phase transition in pre-S 2 mutant LHBS (+) cells (∆2 w/DMSO versus ∆2 w/SAHA in G 1 phase; Figure 4A and B). Colony formation assays also showed that pre-S 2 mutant LHBS increased cell proliferation when it was present in the cancerous T24 and HuH7 cells and non-cancerous WRL-68 hepatocytes (control w/ DMSO versus ∆2 w/DMSO, Figure 4C ). SAHA treatment preferentially killed the cancerous T24 and HuH7 cells compared with the noncancerous WRL-68 hepatocytes (T24 w/SAHA and HuH7 w/SAHA versus WRL-68 w/SAHA; Figure 4C ). More importantly, although SAHA was not significantly cytotoxic to WRL-68 cells, it efficiently killed these cells when they were carrying the pre-S 2 mutant LHBS (control w/SAHA versus ∆2 w/SAHA; Figure 4C ), which suggested that SAHA efficiently eradicates pre-S 2 mutant LHBS (+) hepatocytes.
Pre-S 2 mutant LHBS transgenic mice exhibited pro-oncogenic phenotypes that were inhibited by SAHA
We generated transgenic mice carrying the pre-S 2 mutant LHBS gene under control of the mouse albumin promoter (26) . The liver sections showed pre-dysplastic morphologies characterized by an increased nuclear/cytoplasmic ratio and binucleation ( Figure 5A and B) . Analyses of the cell proliferation rates, shown by the PCNA signals detected using immunohistochemical staining, found that transgenic mice at 6 months old overexpressed PCNA, whereas the C57BL/6 control mice at the same age did not ( Figure 5C ). Furthermore, the liver tissue from transgenic mice showed phenotypes of p27 Kip1 degradation and Cdk2 activation (Figure 5D ), the pro-oncogenic phenotypes observed in the in vitro cell models.
To determine the antioncogenic effects of SAHA in these transgenic mice, five 6-month-old transgenic mice and the same number of ageand sex-matched control mice were injected (50 mg/ml/day; i.p.) with SAHA or mock treated for 14 days, respectively. After SAHA treatment, the pre-S 2 mutant LHBS (+) cells with an increased nuclear/cytoplasmic ratio and binucleation were largely decreased, whereas the HBS levels were not notably affected ( Figure 5E ). Results of the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays showed no observable apoptotic cells, which indicated that SAHA had caused no significant cytotoxicity at the administered dose (Supplementary Figure 3 , available at Carcinogenesis Online). Serum ALT tests showed that SAHA treatment did not cause significant liver inflammation (Supplementary Figure 4 , available at Carcinogenesis Online). SAHA treatments also greatly downregulated the cell proliferation markers PCNA and Ki67 RNA levels aberrantly elevated in the pre-S 2 mutant transgenic mice ( Figure 5F ). As a result of TBP2 upregulation, the levels of p27
Kip1 protein and Cdk2 T160 phosphorylation recovered to their normal states ( Figure 5G) . Also, the pre-S 2 mutant LHBS-induced PCNA overexpression was nearly completely abolished, shown by the decrease in the number of cells highly expressing the PCNA protein detected using immunohistochemical analysis ( Figure 5H ). Taken together, the lines of evidence in our in vitro and in vivo studies clearly showed that HDAC inhibitors such as SAHA reversed pre-S 2 mutant LHBS-induced cell cycle progression and proliferation and therefore are good potential drugs for chemoprevention in HBV chronic carriers in high risk to HCC.
Discussion
To prevent the disease progression from chronic HBV infection to HCC still remains a major challenge. Previously, we identified that type II GGHs harboring the pre-S 2 mutant LHBS represent the preneoplastic lesions and provide a biomarker to identify the high-risk patients. In this study, we found the decrease of p27 Kip1 in the type II GGHs in HCC patients via the interaction between the pre-S 2 mutant LHBS and JAB1, suggesting p27
Kip1 degradation as a biomarker for chronic HBV carriers in high risk to HCC. We also found that HDAC inhibitor SAHA increased transcription of the tumor suppressor TBP2 through facilitating binding of the transcription factor NF-Y to TBP2 promoter, which, in turn, increased the TBP2-JAB1 complex. Through this pathway, SAHA was able to attenuate the pre-S 2 mutant LHBS-induced JAB1-p27
Kip1 interaction and recover normal cell cycle checkpoint disturbed by such an interaction. This effect was observed in in vitro cultured cells and in vivo pre-S 2 mutant transgenic mice, which exhibited prooncogenic phenotypes including large cell dysplasia and enhanced proliferation. Data summarized in Figure 6 show that SAHA reduced PCNA overexpression and p27
Kip1 degradation, which inhibited pre-S 2 mutant LHBS-induced cell proliferation and cell cycle progression. Earlier studies (16, (27) (28) (29) also showed that, as an HDAC inhibitor, SAHA abolished cyclin A overexpression and Akt/mTOR and vascular endothelial growth factor activation, all of which were found to be stimulated by the pre-S 2 mutant LHBS in our earlier studies. Taking all these findings together, we conclude that SAHA is a promising potential chemopreventive agent for HCC in chronic HBV carriers harboring type II GGH preneoplastic lesions. A recent study has also reported that the ubiquitin ligase S-phase kinase-associated protein 2 (SKP2) were commonly increased in HCC and resulted in p27
Kip1 degradation (30) . In this study, we examined the SKP2 mRNA and protein levels in the human HuH7 cells carrying the pre-S 2 mutant LHBS but observed no significant changes in them (Supplementary Figure 5 , available at Carcinogenesis Online). This finding indicates that the pre-S 2 mutant LHBS-induced p27
Kip1 degradation is mainly through its interaction with JAB1 rather than SKP2-mediated ubiquitination activity.
Recent studies have reported that JAB1 overexpression and p27
Kip1 degradation were commonly seen in HCC, suggesting that they were attractive molecular targets for HCC therapy and chemoprevention of recurrence after hepatectomy treatments (31, 32) . In this study, we also observed p27 Kip1 degradation in type II GGHs harboring preneoplastic lesions and found that HDAC inhibitor SAHA caused p27
Kip1 stabilization through inducing TBP2 expression to disrupt JAB1-p27 Kip1 complex. Therefore, it is suggested that the liver tissues obtained from the HCC patients receiving hepatectomy surgery and chronic HBV carriers receiving liver biopsy procedures should be examined for p27
Kip1 levels in order to decide whether they are suitable for chemoprevention using SAHA. Recently, SAHA and another HDAC inhibitor sodium butyrate were shown to exhibit chemopreventive activities for lung and colon cancers through epigenetically regulating some carcinogenesis-associated genes (33, 34) . These findings were consistent with ours in HBV-induced HCC. HDAC inhibitors are responsible for modifying the activity of diverse types of histone and non-histone proteins, including transcription factors and signal transduction mediators that possess tumor-associated properties (23) . They downregulate the expression of oncogenic genes, such as TGF-β, telomerase, vascular endothelial growth factor, cyclin A and abl genes (27) (28) (29) . In then pulled down using streptavidin beads. The pull-down protein-DNA complexes were analyzed by western blotting using a mouse anti-NF-YA antibody. The relative amounts of NF-YA bound to the DNA probes (bound) to the input NF-YA for DAPA experiments (input) in the same cells were calculated and indicated at the bottom of the gel images. (E) Dependence of TBP2 for SAHA-induced p27
Kip1 stabilization in the pre-S 2 mutant LHBS (+) HuH7 cells, detected using western blotting. The cells stably expressing wild-type (WT) LHBS, pre-S 2 mutant (Δ2) LHBS or vehicle control (V) were transduced with lentiviruses carrying TBP2-specific siRNA (lanes 7-9) or those carrying GFP siRNA as a negative control (lanes 4-6) for 48 h and then treated with SAHA (5 µM, lanes 4-9) or mock treated (lanes 1-3) for another 24 h before harvest. (F) Increased interaction between JAB1 and TBP2 was detected using co-immunoprecipitation assays. HuH7 cells carrying wild-type (WT) LHBS, pre-S 2 mutant (Δ2) LHBS or vehicle control (V) were treated with SAHA (5 µM) or vehicle control (DMSO) for 24 h and then harvested for co-immunoprecipitation assays. SAHA greatly increased the interaction between JAB1 and TBP2. (G) SAHA disrupted the interaction of JAB1 with p27
Kip1 in the pre-S 2 mutant LHBS (+) HuH7 cells. Cells were treated with SAHA (5 µM) or vehicle control (DMSO) for 24 h, followed by the proteasome inhibitor MG132 (10 µM) for 4 h, and then analyzed using co-immunoprecipitation assays. The increased JAB1-p27
Kip1 interaction in pre-S 2 mutant LHBS (+) cells recovered to normal levels after SAHA treatment.
← contrast, they also upregulate the expression of the tumor-suppressive genes, such as p53, p21, gelsolin and a group of proapoptotic genes, such as Bcl2, Bim and caspase 3 (23) . In this study, we found that SAHA increased direct binding of the transcription factor NF-Y to the promoter of the tumor-suppressor TBP2, an upstream inhibitor of thioredoxin, which presents with oncogenic properties through affecting reduction-oxidation homeostasis and inhibiting apoptosis (35) . Previous studies have shown that the function of NF-Y as a transcription factor was activated by acetylation, suggesting that SAHA might have induced NF-Y acetylation and, consequently, its activation (36) . It was also reported that in HDAC inhibitor-induced apoptosis, the production of proapoptotic reactive oxygen species was important (37) . We previously (15) found that the pre-S 2 mutant LHBS induced reactive oxygen species generation, which might augment the killing effects of HDAC inhibitors on cells and explain why SAHA killed non-cancerous WRL-68 cells carrying the pre-S 2 mutant LHBS more efficiently than those carrying the wild-type LHBS ( Figure 4C ). Interestingly, we found that in the transgenic mice SAHA was able to decrease the proliferation marker PCNA without causing significant toxicity to the liver, indicated by negative results of the TUNEL assays (Supplementary Figure 3 , available at Carcinogenesis Online). This finding suggested that SAHA affected the functions of its target molecules, but was also efficiently metabolized and detoxicated via the strong xenobiotic metabolizing activity in the liver. HCC caused by chronic HBV infection is usually a slow process with an incubation period of >20 years. An active chemopreventive approach should therefore be undertaken in chronic HBV carriers during the long years of viral persistence, especially in those that represent high-risk populations. So far, most of the reported chemopreventive agents for HCC are phytochemicals presenting general antioxidant activities to defeat the oxidative stress caused by hepatic inflammation and necrosis (26, 38, 39) . Common examples are chlorophylin, silymarin, vitamin E and vitamin A and its derivatives, such as polyprenoic acid. However, it has been found that although these chemicals prevented HCC carcinogenesis if administered at the early stage before the initiation of the carcinogenic process, some of them had no protective effects once pre-dysplastic phenotypes had emerged (26) . In fact, antioxidant activities in cancers have been found to increase cancer cell proliferation, resulting in resistance to chemotherapies (40) . HDAC inhibitor, however, is different in that it has a highly selective killing effect on cancerous rather than on healthy cells, and it has not been found to promote the growth of pre-dysplastic cells (23, 41) . In this study, we showed that HDAC inhibitor SAHA inhibited proliferation of pre-S 2 mutant LHBS (+) cancerous and non-cancerous cells, indicating that SAHA not only kills HCC cells but that it also selectively eradicates pre-S 2 mutant LHBS (+) noncancerous cells, which are prone to cancer. Given that, HDAC inhibitor stands as a good potential preventive agent for HCC and it should be particularly beneficial to the cells exhibiting high pro-oncogenic phenotypes.
Previous and our current studies have found that some HDAC inhibitors exhibited chemopreventive activities for cancer. Thus, to be widely applied to large population of healthy HBV carriers in daily base, using food-derived natural compounds would be a practical way to chemically prevent HCC in healthy HBV carriers. Our preliminary data found that the natural HDAC inhibitor sulforaphane, extracted from broccoli, selectively killed cancerous 6 . Schematic representation for the anticarcinogenic effects of SAHA on pre-S 2 mutant LHBS-induced HCC. The pre-S 2 mutant LHBS induces endoplasmic reticulum stress-mediated oxidative stress and DNA damage that cause gene mutations and genomic instability. It also induces cyclin A overexpression and p27
Kip1 degradation, which causes cell cycle progression. In addition, we recently showed that the pre-S 2 mutant LHBS activates the Akt/mTOR proliferative signaling pathway and increases cell proliferation. These multiple effects greatly accelerate the hepatocellular carcinogenic process in chronic HBV carriers and indicate that the pre-S 2 mutant LHBS is a significant viral oncoprotein. The concerted activities of SAHA to block cyclin A and PCNA expression, Akt/mTOR pathway activation and p27
Kip1 degradation in a JAB1-dependent manner support the hypothesis that SAHA induces significant remission of pre-S 2 mutant LHBS-induced oncogenic phenotypes and will, therefore, be an effective chemopreventive against pre-S 2 mutant LHBS-associated HCC. cells (data not shown), which supports the notion that sulforaphane might be a natural product for chemoprevention (42) . Thus, this study provides a clear molecular mechanism by which the HDAC inhibitor SAHA selectively abolished pre-S 2 mutant LHBS-induced pro-oncogenic phenotypes. The findings here allow one to conclude that HDAC inhibitors are promising chemopreventive agents for HCC.
In summary, this study provides in vitro and in vivo evidence to suggest that the pre-S 2 mutant LHBS exhibited pro-oncogenic properties for HCC development, which can be greatly inhibited by HDAC inhibitor SAHA. The underlying molecular mechanism for such an inhibitory effect was also elucidated. Because of the lack of an ideal candidate agent for the chemoprevention of the progression from chronic HBV infection to HCC, HDAC inhibitor SAHA will be a potential candidate for the high-risk chronic HBV patients who present with the pre-S 2 mutant LHBS in the serum or type II GGHs in the liver tissues.
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